CRSP Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own CRSP shares is 562, representing 74.66% of the company's common stock.

BANK OF NEW YORK MELLON CORP, in the last quarter, reduced its stake in CRSP by -30.2% restricting it's holding to 75.31 thousand shares of worth nearly $5.13M. STATE STREET CORP also lessened -14.73% of the CRSP shares from its portfolio, reducing its holding to 1.5 million shares of worth $101.91M. CREDIT SUISSE AG/ also shunned CRSP shares holding by -17.9% last quarter which brought its holding to 719.31 thousand shares worth $49.03M.

As per its latest 13F filing, ALLSPRING GLOBAL INVESTMENTS HOLDINGS, LLC increased its stake in CRSP by 113.19% in the last quarter. The institutional holder raised its holding to 78.92 thousand shares having worth more than $5.38M. VAN ECK ASSOCIATES CORP also added 6.05% more shares of CRSP to its portfolio, raising its holding to 71.94 thousand shares of worth $4.90M. ECOR1 CAPITAL, LLC also increased its CRSP shares holding by 100% which brought its holding to 1.39 million shares worth $94.69M.

The insider with the most stakes in CRSP is Novak Rodger , President at the company. Additionally, CRSP stock is highly held by Chief Executive Officer Kulkarni Samarth and director Bolzon Bradley J PhD among others.

Company executives, directors, and other insiders own 1.71% percent of CRISPR Therapeutics AG's stock. Within the last six months, there have been 4 transaction(s) in which CRSP insiders have sold stock, totaling 27.26K shares. Insiders that have sold shares include KULKARNI SAMARTH, KASINGER JAMES R., and BRUNO JULIANNE.

There have been 0 transaction(s) during the past 6-months in which CRISPR Therapeutics AG insiders have bought stock, totalling 0 shares

Around 667.22K CRISPR Therapeutics AG shares are held by insiders, which represents about 1.71% of CRSP stock.

CRSP President, Novak Rodger holds the largest portfolio of the company's shares. CRSP shares owned by Novak total nearly 573.01 thousand.

NEA MANAGEMENT COMPANY, LLC is the largest institutional owner in CRSP which holds 1.59 million shares worth $180.41M or 1.94% of the total CRSP shares outstanding followed by ALLSPRING GLOBAL INVESTMENTS HOLDINGS, LLC with ownership of 78.92 thousand shares representing 0.1% of the CRSP ownership. BANK OF NEW YORK MELLON CORP is the third largest stakeholder with 75.31 thousand shares or 0.1% of the ownership worth more than $5.13M.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the CRSP is concerned, it is a stock which is optionable.

Number of CRSP shares short is 19.10M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 85.35M shares of CRSP are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, CRSP has 83.90M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for CRSP is 9.89.